JP2011528019A - Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体 - Google Patents
Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体 Download PDFInfo
- Publication number
- JP2011528019A JP2011528019A JP2011517910A JP2011517910A JP2011528019A JP 2011528019 A JP2011528019 A JP 2011528019A JP 2011517910 A JP2011517910 A JP 2011517910A JP 2011517910 A JP2011517910 A JP 2011517910A JP 2011528019 A JP2011528019 A JP 2011528019A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- sulfonyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004885 piperazines Chemical class 0.000 title abstract description 4
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title description 2
- 101000935123 Homo sapiens Voltage-dependent N-type calcium channel subunit alpha-1B Proteins 0.000 title 1
- 102100025342 Voltage-dependent N-type calcium channel subunit alpha-1B Human genes 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 185
- 229910052739 hydrogen Inorganic materials 0.000 claims description 68
- 239000001257 hydrogen Substances 0.000 claims description 67
- 150000003839 salts Chemical class 0.000 claims description 60
- 229910052757 nitrogen Inorganic materials 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 52
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 42
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 39
- 229910052799 carbon Inorganic materials 0.000 claims description 39
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
- 208000002193 Pain Diseases 0.000 claims description 25
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 230000036407 pain Effects 0.000 claims description 22
- 150000002431 hydrogen Chemical group 0.000 claims description 20
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- -1 C 1-4 haloalkyl compound Chemical class 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- AJVSYMZFWALLGQ-UHFFFAOYSA-N pyridin-4-yl-[4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CN=CC=2)CC1 AJVSYMZFWALLGQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- QPGXZEFRKPOXEQ-UHFFFAOYSA-N [4-(4-chlorophenyl)sulfonylpiperazin-1-yl]-pyridin-2-ylmethanone Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2N=CC=CC=2)CC1 QPGXZEFRKPOXEQ-UHFFFAOYSA-N 0.000 claims description 3
- UPQPLCHRUISXHI-UHFFFAOYSA-N [4-(4-chlorophenyl)sulfonylpiperazin-1-yl]-pyridin-4-ylmethanone Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CN=CC=2)CC1 UPQPLCHRUISXHI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- AVEHXFLCCVKIJC-UHFFFAOYSA-N pyridin-2-yl-[4-[4-(trifluoromethoxy)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2N=CC=CC=2)CC1 AVEHXFLCCVKIJC-UHFFFAOYSA-N 0.000 claims description 3
- QEKSLQRAXJJTPG-UHFFFAOYSA-N pyridin-2-yl-[4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2N=CC=CC=2)CC1 QEKSLQRAXJJTPG-UHFFFAOYSA-N 0.000 claims description 3
- PWAKGVGKAHXHDH-UHFFFAOYSA-N pyridin-4-yl-[4-[4-(trifluoromethoxy)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CN=CC=2)CC1 PWAKGVGKAHXHDH-UHFFFAOYSA-N 0.000 claims description 3
- RQTNOADYINLNMQ-UHFFFAOYSA-N (4-chloropyridin-2-yl)-[4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2N=CC=C(Cl)C=2)CC1 RQTNOADYINLNMQ-UHFFFAOYSA-N 0.000 claims description 2
- APVGPFDESPEZGP-UHFFFAOYSA-N [4-(3-chlorophenyl)sulfonylpiperazin-1-yl]-pyridin-4-ylmethanone Chemical compound ClC1=CC=CC(S(=O)(=O)N2CCN(CC2)C(=O)C=2C=CN=CC=2)=C1 APVGPFDESPEZGP-UHFFFAOYSA-N 0.000 claims description 2
- XAYONIMFDMHENW-UHFFFAOYSA-N [4-(4-chlorophenyl)sulfonylpiperazin-1-yl]-(4-chloropyridin-2-yl)methanone Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2N=CC=C(Cl)C=2)CC1 XAYONIMFDMHENW-UHFFFAOYSA-N 0.000 claims description 2
- XOBAXZSTRVZHKK-UHFFFAOYSA-N [4-[3,5-bis(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-pyridin-4-ylmethanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(S(=O)(=O)N2CCN(CC2)C(=O)C=2C=CN=CC=2)=C1 XOBAXZSTRVZHKK-UHFFFAOYSA-N 0.000 claims description 2
- BFPVJYMYRIBFPY-UHFFFAOYSA-N [4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-pyridin-2-ylmethanone Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)N2CCN(CC2)C(=O)C=2N=CC=CC=2)=C1 BFPVJYMYRIBFPY-UHFFFAOYSA-N 0.000 claims description 2
- QJESEXXXDOHRDT-UHFFFAOYSA-N [4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-pyridin-4-ylmethanone Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)N2CCN(CC2)C(=O)C=2C=CN=CC=2)=C1 QJESEXXXDOHRDT-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- LXVHOYIKKOXFLP-UHFFFAOYSA-N pyridin-2-yl-[4-[3-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)N2CCN(CC2)C(=O)C=2N=CC=CC=2)=C1 LXVHOYIKKOXFLP-UHFFFAOYSA-N 0.000 claims description 2
- AMYQTSQXIGNIKB-UHFFFAOYSA-N pyridin-4-yl-[4-[3-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)N2CCN(CC2)C(=O)C=2C=CN=CC=2)=C1 AMYQTSQXIGNIKB-UHFFFAOYSA-N 0.000 claims description 2
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 23
- 239000011575 calcium Substances 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 108090000312 Calcium Channels Proteins 0.000 abstract description 6
- 102000003922 Calcium Channels Human genes 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 113
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 56
- 239000000243 solution Substances 0.000 description 55
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 50
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
- 239000000203 mixture Substances 0.000 description 35
- 239000011541 reaction mixture Substances 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 239000002904 solvent Substances 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 239000007787 solid Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- 239000003643 water by type Substances 0.000 description 15
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000002265 prevention Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 239000003446 ligand Substances 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 239000013058 crude material Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 238000005191 phase separation Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000012799 strong cation exchange Methods 0.000 description 8
- SQXBFRFABWYXTK-UHFFFAOYSA-N 1-[4-(trifluoromethyl)phenyl]sulfonylpiperazine Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1CCNCC1 SQXBFRFABWYXTK-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- YXRANDHKVRJEIY-VIFPVBQESA-N (3s)-3-methyl-1-[4-(trifluoromethyl)phenyl]sulfonylpiperazine Chemical compound C1CN[C@@H](C)CN1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 YXRANDHKVRJEIY-VIFPVBQESA-N 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- PMDHIMMPXRSDML-UHFFFAOYSA-N 2-methylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC=N1 PMDHIMMPXRSDML-UHFFFAOYSA-N 0.000 description 6
- OZDCZHDOIBUGAJ-UHFFFAOYSA-N 4-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=C(S(Cl)(=O)=O)C=C1 OZDCZHDOIBUGAJ-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- OXPJTNQAIGKPKL-UHFFFAOYSA-N (4-bromopyridin-2-yl)-[4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2N=CC=C(Br)C=2)CC1 OXPJTNQAIGKPKL-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
- FZXBFLDTSJWYIJ-LBPRGKRZSA-N (4-chloropyridin-2-yl)-[(2s)-2-methyl-4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound C([C@@H]1C)N(S(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)CCN1C(=O)C1=CC(Cl)=CC=N1 FZXBFLDTSJWYIJ-LBPRGKRZSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102400000096 Substance P Human genes 0.000 description 3
- 101800003906 Substance P Proteins 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 230000007831 electrophysiology Effects 0.000 description 3
- 238000002001 electrophysiology Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- PSAYJRPASWETSH-UHFFFAOYSA-N pyridine-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CC=N1 PSAYJRPASWETSH-UHFFFAOYSA-N 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- XJEGPOUVRRGVIS-FVGYRXGTSA-N (2s)-1-(4-chlorophenyl)sulfonyl-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1S(=O)(=O)C1=CC=C(Cl)C=C1 XJEGPOUVRRGVIS-FVGYRXGTSA-N 0.000 description 2
- SHFVMXYJQFRLHJ-SECBINFHSA-N (3r)-1-(4-chlorophenyl)sulfonyl-3-methylpiperazine Chemical compound C1CN[C@H](C)CN1S(=O)(=O)C1=CC=C(Cl)C=C1 SHFVMXYJQFRLHJ-SECBINFHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- RPHHYRNGCJYQSP-UHFFFAOYSA-N 4-bromopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Br)=CC=N1 RPHHYRNGCJYQSP-UHFFFAOYSA-N 0.000 description 2
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 2
- AXJKHMPAWFRPAR-UHFFFAOYSA-N 5-pyridin-2-ylpyridine-2-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC=C1C1=CC=CC=N1 AXJKHMPAWFRPAR-UHFFFAOYSA-N 0.000 description 2
- 229930183010 Amphotericin Natural products 0.000 description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 0 C*C(C)(C=*C=*1)C=C1C(N(CC1)C*(*)CN1S(c1c(*)c(*)c(C)c(*)c1)(=O)=O)=O Chemical compound C*C(C)(C=*C=*1)C=C1C(N(CC1)C*(*)CN1S(c1c(*)c(*)c(C)c(*)c1)(=O)=O)=O 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 101150003085 Pdcl gene Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GQDQSQOCYMUPOY-VIFPVBQESA-N [(2s)-2-methylpiperazin-1-yl]-pyridin-2-ylmethanone Chemical compound C[C@H]1CNCCN1C(=O)C1=CC=CC=N1 GQDQSQOCYMUPOY-VIFPVBQESA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 201000007637 bowel dysfunction Diseases 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 150000004675 formic acid derivatives Chemical class 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical group CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000009155 sensory pathway Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 2
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 108091058550 ω-conotoxin Proteins 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- IJSAKJMCEJBHKT-UHFFFAOYSA-N (2-methylpyridin-4-yl)-[4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound C1=NC(C)=CC(C(=O)N2CCN(CC2)S(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)=C1 IJSAKJMCEJBHKT-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- VBRZNIOGQGHCIM-SBSPUUFOSA-N (2r)-2-methyl-1-[4-(trifluoromethyl)phenyl]sulfonylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 VBRZNIOGQGHCIM-SBSPUUFOSA-N 0.000 description 1
- VBRZNIOGQGHCIM-FVGYRXGTSA-N (2s)-2-methyl-1-[4-(trifluoromethyl)phenyl]sulfonylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 VBRZNIOGQGHCIM-FVGYRXGTSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-YFKPBYRVSA-N (2s)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1 JOMNTHCQHJPVAZ-YFKPBYRVSA-N 0.000 description 1
- MMIWDPMBWOTICQ-YFKPBYRVSA-N (2s)-2-methylpiperazine-1-carboxylic acid Chemical compound C[C@H]1CNCCN1C(O)=O MMIWDPMBWOTICQ-YFKPBYRVSA-N 0.000 description 1
- YSXJXBBESJSSDY-UQKRIMTDSA-N (3-methylpyridin-2-yl)-[(2s)-2-methyl-4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone;hydrochloride Chemical compound Cl.C([C@@H]1C)N(S(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)CCN1C(=O)C1=NC=CC=C1C YSXJXBBESJSSDY-UQKRIMTDSA-N 0.000 description 1
- MNCORDODJXFOSM-UHFFFAOYSA-N (3-methylpyridin-2-yl)-[4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound CC1=CC=CN=C1C(=O)N1CCN(S(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)CC1 MNCORDODJXFOSM-UHFFFAOYSA-N 0.000 description 1
- VFCUTJXFHGFAKS-SECBINFHSA-N (3R)-3-methyl-4-[4-(trifluoromethyl)phenyl]sulfonylpiperazine-1-carboxylic acid Chemical compound C[C@@H]1CN(C(O)=O)CCN1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 VFCUTJXFHGFAKS-SECBINFHSA-N 0.000 description 1
- JRIOWAGJUZFDEX-VIFPVBQESA-N (3S)-3-methyl-4-(pyridine-2-carbonyl)piperazine-1-carboxylic acid Chemical compound C[C@H]1CN(C(O)=O)CCN1C(=O)C1=CC=CC=N1 JRIOWAGJUZFDEX-VIFPVBQESA-N 0.000 description 1
- IQVSXOWZPYKBBR-VIFPVBQESA-N (3S)-4-(4-chlorophenyl)sulfonyl-3-methylpiperazine-1-carboxylic acid Chemical compound C[C@H]1CN(C(O)=O)CCN1S(=O)(=O)C1=CC=C(Cl)C=C1 IQVSXOWZPYKBBR-VIFPVBQESA-N 0.000 description 1
- YXRANDHKVRJEIY-SECBINFHSA-N (3r)-3-methyl-1-[4-(trifluoromethyl)phenyl]sulfonylpiperazine Chemical compound C1CN[C@H](C)CN1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 YXRANDHKVRJEIY-SECBINFHSA-N 0.000 description 1
- SSEJSSNDPMMWBQ-YFKPBYRVSA-N (3s)-3-methylpiperazine-1-carboxylic acid Chemical compound C[C@H]1CN(C(O)=O)CCN1 SSEJSSNDPMMWBQ-YFKPBYRVSA-N 0.000 description 1
- KFJQSKGXEYBYFY-UHFFFAOYSA-N (4-pyridin-2-ylpyridin-2-yl)-[4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2N=CC=C(C=2)C=2N=CC=CC=2)CC1 KFJQSKGXEYBYFY-UHFFFAOYSA-N 0.000 description 1
- CWGMPMJXTQTAFW-UHFFFAOYSA-N (6-methylpyridin-2-yl)-[4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound CC1=CC=CC(C(=O)N2CCN(CC2)S(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)=N1 CWGMPMJXTQTAFW-UHFFFAOYSA-N 0.000 description 1
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- HJFSDIPLWLUGRT-UHFFFAOYSA-N 1-(2-sulfamoylphenyl)-3-(1,3-thiazol-2-yl)urea Chemical class NS(=O)(=O)C1=CC=CC=C1NC(=O)NC1=NC=CS1 HJFSDIPLWLUGRT-UHFFFAOYSA-N 0.000 description 1
- YFRBKEVUUCQYOW-UHFFFAOYSA-N 1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C(C=N1)=CC=C1OC1=CC=C(CCN(CC2)C3CCC3)C2=C1 YFRBKEVUUCQYOW-UHFFFAOYSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- SOQIDYYUSMPIDR-UHFFFAOYSA-N 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC=N1 SOQIDYYUSMPIDR-UHFFFAOYSA-N 0.000 description 1
- NXMZBNYLCVTRGB-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-3-(4-methylsulfonylphenyl)pyrazolo[1,5-b]pyridazine Chemical compound C1=CC(OCC)=CC=C1C1=NN(N=CC=C2)C2=C1C1=CC=C(S(C)(=O)=O)C=C1 NXMZBNYLCVTRGB-UHFFFAOYSA-N 0.000 description 1
- BZFGKBQHQJVAHS-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(C(F)(F)F)=C1 BZFGKBQHQJVAHS-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LMHIBYREWJHKNZ-UHFFFAOYSA-N 3-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=CN=C1C(O)=O LMHIBYREWJHKNZ-UHFFFAOYSA-N 0.000 description 1
- DRCNJUKCMKDMCX-HNNXBMFYSA-N 4-[(3s)-3-methyl-4-(2-methylpyridine-4-carbonyl)piperazin-1-yl]sulfonylbenzonitrile Chemical compound C([C@@H]1C)N(S(=O)(=O)C=2C=CC(=CC=2)C#N)CCN1C(=O)C1=CC=NC(C)=C1 DRCNJUKCMKDMCX-HNNXBMFYSA-N 0.000 description 1
- CMZIUDLOWIGHAP-AWEZNQCLSA-N 4-[(3s)-3-methyl-4-(pyridine-2-carbonyl)piperazin-1-yl]sulfonylbenzonitrile Chemical compound C([C@@H]1C)N(S(=O)(=O)C=2C=CC(=CC=2)C#N)CCN1C(=O)C1=CC=CC=N1 CMZIUDLOWIGHAP-AWEZNQCLSA-N 0.000 description 1
- KNBSFUSBZNMAKU-UHFFFAOYSA-N 4-bromo-2-methylbenzenesulfonyl chloride Chemical compound CC1=CC(Br)=CC=C1S(Cl)(=O)=O KNBSFUSBZNMAKU-UHFFFAOYSA-N 0.000 description 1
- NNMYRMGMVLMQAY-UHFFFAOYSA-N 4-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=N1 NNMYRMGMVLMQAY-UHFFFAOYSA-N 0.000 description 1
- NRPQELCNMADTOZ-OAQYLSRUSA-N 4-cyano-n-[(2r)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-n-pyridin-2-ylbenzamide Chemical compound C([C@@H](C)N1CCN(CC1)C=1C=2OCCOC=2C=CC=1)N(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 NRPQELCNMADTOZ-OAQYLSRUSA-N 0.000 description 1
- DBMFYTQPPBBKHI-UHFFFAOYSA-N 4-cyanobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(C#N)C=C1 DBMFYTQPPBBKHI-UHFFFAOYSA-N 0.000 description 1
- 108091005482 5-HT4 receptors Proteins 0.000 description 1
- 229940124801 5-HT6 antagonist Drugs 0.000 description 1
- 108091005435 5-HT6 receptors Proteins 0.000 description 1
- LTUUGSGSUZRPRV-UHFFFAOYSA-N 6-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=CC(C(O)=O)=N1 LTUUGSGSUZRPRV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000010183 Bradykinin receptor Human genes 0.000 description 1
- 108050001736 Bradykinin receptor Proteins 0.000 description 1
- PXWVDDVZJRRCKT-LSLKUGRBSA-N CCC(C)OC(=O)N1CCN(C[C@@H]1C)S(=O)(=O)C2=C(C=C(C=C2)Br)C Chemical compound CCC(C)OC(=O)N1CCN(C[C@@H]1C)S(=O)(=O)C2=C(C=C(C=C2)Br)C PXWVDDVZJRRCKT-LSLKUGRBSA-N 0.000 description 1
- KTNPKOMMPTUDLB-VEDVMXKPSA-N CCC(C)OC(=O)N1CCNC[C@H]1C Chemical compound CCC(C)OC(=O)N1CCNC[C@H]1C KTNPKOMMPTUDLB-VEDVMXKPSA-N 0.000 description 1
- VFCUTJXFHGFAKS-VIFPVBQESA-N C[C@H]1CN(C(O)=O)CCN1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 Chemical compound C[C@H]1CN(C(O)=O)CCN1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 VFCUTJXFHGFAKS-VIFPVBQESA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 102100032404 Cholinesterase Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 1
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 229940122165 Glycine receptor antagonist Drugs 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 241001417539 Liza Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102100037601 P2X purinoceptor 4 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N Picolinic acid Natural products OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- ULHSQWWLOIOMHR-CYBMUJFWSA-N [(2r)-4-(4-chlorophenyl)sulfonyl-2-methylpiperazin-1-yl]-pyridin-2-ylmethanone Chemical compound C([C@H]1C)N(S(=O)(=O)C=2C=CC(Cl)=CC=2)CCN1C(=O)C1=CC=CC=N1 ULHSQWWLOIOMHR-CYBMUJFWSA-N 0.000 description 1
- RFBMAOZWUVWVRN-JTQLQIEISA-N [(2s)-2-methylpiperazin-1-yl]-(2-methylpyridin-4-yl)methanone Chemical compound C[C@H]1CNCCN1C(=O)C1=CC=NC(C)=C1 RFBMAOZWUVWVRN-JTQLQIEISA-N 0.000 description 1
- UHQUVRKXKZRUOW-ZDUSSCGKSA-N [(3s)-4-(4-chlorophenyl)sulfonyl-3-methylpiperazin-1-yl]-pyridin-2-ylmethanone Chemical compound C([C@@H]1C)N(C(=O)C=2N=CC=CC=2)CCN1S(=O)(=O)C1=CC=C(Cl)C=C1 UHQUVRKXKZRUOW-ZDUSSCGKSA-N 0.000 description 1
- DZLULKAXJLHZQE-HNNXBMFYSA-N [4-(azetidin-1-yl)pyridin-2-yl]-[(2s)-2-methyl-4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound C([C@@H]1C)N(S(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)CCN1C(=O)C(N=CC=1)=CC=1N1CCC1 DZLULKAXJLHZQE-HNNXBMFYSA-N 0.000 description 1
- VOHWBAOQBGVHFB-UQKRIMTDSA-N [4-(dimethylamino)pyridin-2-yl]-[(2s)-2-methyl-4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone;hydrochloride Chemical compound Cl.C([C@@H]1C)N(S(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)CCN1C(=O)C1=CC(N(C)C)=CC=N1 VOHWBAOQBGVHFB-UQKRIMTDSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002582 adenosine A1 receptor agonist Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 229960002133 almotriptan Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- SYOMWBITNYGIPT-UQKRIMTDSA-N formic acid;(2-methylpyridin-4-yl)-[(2s)-2-methyl-4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone Chemical compound OC=O.C([C@@H]1C)N(S(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)CCN1C(=O)C1=CC=NC(C)=C1 SYOMWBITNYGIPT-UQKRIMTDSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002284 frovatriptan Drugs 0.000 description 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- TZDUHAJSIBHXDL-UHFFFAOYSA-N gabapentin enacarbil Chemical compound CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1 TZDUHAJSIBHXDL-UHFFFAOYSA-N 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000002430 glycine receptor antagonist Substances 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- WROHEWWOCPRMIA-UHFFFAOYSA-N gsk-189,254 Chemical compound N1=CC(C(=O)NC)=CC=C1OC1=CC=C(CCN(CC2)C3CCC3)C2=C1 WROHEWWOCPRMIA-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- YQYJSBFKSSDGFO-FWAVGLHBSA-N hygromycin A Chemical compound O[C@H]1[C@H](O)[C@H](C(=O)C)O[C@@H]1Oc1ccc(\C=C(/C)C(=O)N[C@@H]2[C@@H]([C@H]3OCO[C@H]3[C@@H](O)[C@@H]2O)O)cc1O YQYJSBFKSSDGFO-FWAVGLHBSA-N 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Natural products OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229950007396 lecozotan Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000036278 prepulse Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002400 pro-nociceptive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960003312 retigabine Drugs 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012437 strong cation exchange chromatography Methods 0.000 description 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 1
- 238000003883 substance clean up Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- FMLPQHJYUZTHQS-MRVPVSSYSA-N tert-butyl (3r)-3-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-MRVPVSSYSA-N 0.000 description 1
- YTYRNAWFSOMFGF-UHFFFAOYSA-N tert-butyl 4-[4-(trifluoromethyl)phenyl]sulfonylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 YTYRNAWFSOMFGF-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 1
- KNJNGVKTAFTUFL-OCMUWRIYSA-N ω-conotoxin Chemical compound N([C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1C(N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CSSC1)C(N)=O)=O)=O)C(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1 KNJNGVKTAFTUFL-OCMUWRIYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
第一の態様において、治療において使用するための式(I)の化合物、又はその医薬として許容し得る塩:
(式中、Xは窒素でありかつYは炭素であり、又はXは炭素でありかつYは窒素であり;
m及びnは独立して、0、1、及び2から選択され;
ここで、存在する場合、各R1は独立して、C1-4アルキル、C1-4アルコキシ、C3-6シクロアルキル、シアノ、NR1aR1b、及びハロゲンから選択され;
R1a及びR1bは独立して、水素、C1-4アルキル、C3-6シクロアルキル、及び4〜6員のヘテロシクリルから選択され;又はR1a及びR1bは、それらが結合する窒素原子と共に、4〜6員の複素環を形成し;
ここで、存在する場合、各R2は、C1-4アルキルであり;
R3は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4ハロアルコキシであり;
R4は、水素又はC1-4アルキルであり;
R5は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4ハロアルコキシであり;
R6は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4ハロアルコキシであり;
そこで、R3、R4、R5、及びR6のうちの少なくとも1つは、水素以外の基である。)。
Xは窒素でありかつYは炭素であり、又はXは炭素でありかつYは窒素であり;
m及びnは独立して、0、1、及び2から選択され;
ここで、存在する場合、各R1は独立して、C1-4アルキル、C1-4アルコキシ、C3-6シクロアルキル、シアノ、NR1aR1b、及びハロゲンから選択され;
R1a及びR1bは独立して、水素、C1-4アルキル、C3-6シクロアルキル、及び4〜6員のヘテロシクリルから選択され;又はR1a及びR1bは、それらが結合する窒素原子と共に、4〜6員の複素環を形成し;
ここで、存在する場合、各R2は、C1-4アルキルであり;
R3は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4ハロアルコキシであり;
R4は、水素又はC1-4アルキルであり;
R5は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4ハロアルコキシであり;
R6は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4ハロアルコキシであり;
そこで、R3、R4、R5、及びR6のうちの少なくとも1つは、水素以外の基であり;
但し、該化合物は、以下の化合物でないことを条件とする:
1-[(4-クロロフェニル)スルホニル]-4-(2-ピリジニルカルボニル)ピペラジン;
1-[(4-クロロフェニル)スルホニル]-4-[(4-クロロ-2-ピリジニル)カルボニル]ピペラジン;
1-[(3-クロロフェニル)スルホニル]-4-(4-ピリジニルカルボニル)ピペラジン;
1-[(4-クロロフェニル)スルホニル]-4-(4-ピリジニルカルボニル)ピペラジン;
1-{[4-クロロ-3-(トリフルオロメチル)フェニル]スルホニル}-4-(2-ピリジニルカルボニル)ピペラジン;
1-[(4-クロロ-2-ピリジニル)カルボニル]-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-{[4-クロロ-3-(トリフルオロメチル)フェニル]スルホニル}-4-(4-ピリジニルカルボニル)ピペラジン;
1-(4-ピリジニルカルボニル)-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-(4-ピリジニルカルボニル)-4-{[3-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-(2-ピリジニルカルボニル)-4-{[3-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-(2-ピリジニルカルボニル)-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-(2-ピリジニルカルボニル)-4-({4-[(トリフルオロメチル)オキシ]フェニル}スルホニル)ピペラジン;
1-(4-ピリジニルカルボニル)-4-({4-[(トリフルオロメチル)オキシ]フェニル}スルホニル)ピペラジン;及び
1-{[3,5-ビス(トリフルオロメチル)フェニル]スルホニル}-4-(4-ピリジニルカルボニル)ピペラジン。
式(I)において、存在する場合、R1が、ピリジル環における4つの考えられ得る炭素原子のうちの任意の1つに結合してもよいことは理解される。
本明細書で使用されるように、用語「アルコキシ」(1つの基として又は1つの基の一部として使用する場合)は、-O-アルキル基を指し、ここで、アルキルは、上述に定義されるとおりである。
本明細書で使用される用語C1-4ハロアルコキシは、1つ以上のハロゲン基、例えば、-O-CF3で置換した、本明細書に定義されるC1-4アルコキシ基を指す。
用語4〜6員の複素環及びその一価のラジカルは、酸素、窒素、及び硫黄から独立して選択される1個又は2個のヘテロ原子を含む4〜6員の飽和単環を指す。このような基の適切な例には、ピロリジニル、ピペリジニル、ピペラジニル、モルフォリニル、チオモルフォリニル、及びアゼチジニルを含む。
第一又は第二の態様に関する一実施態様において、R2はメチルである。第一又は第二の態様に関する別の実施態様において、R2はメチルであり、かつmは1である。第一又は第二の態様に関する特別の実施態様において、式(I)の化合物は、式(Ia)の化合物
第一又は第二の態様に関するより特別の実施態様において、式(I)の化合物は、式(Ib)の化合物
第一又は第二の態様に関する一実施態様において、R5及びR6は独立して、水素及びC1-4ハロアルキルから選択される。第一又は第二の態様に関する1つの特別の実施態様において、R5及びR6は独立して、水素及びトリフルオロメチルから選択される。第一又は第二の態様に関するより特別の実施態様において、R5及びR6は水素である。
第三の態様において、前記化合物は、治療において使用するための式(Ic)の化合物、又はその医薬として許容し得る塩
Xは窒素でありかつYは炭素であり、又はXは炭素でありかつYは窒素であり;
R1は、C1-4アルキル、C1-4アルコキシ、シアノ、又はモルフォリニルを表し;
m及びnは独立して、0〜1の整数を表し;
R2は、C1-4アルキルを表し;
R3は、ハロゲン、シアノ、トリフルオロメチル、トリフルオロメトキシ、又はジフルオロメトキシを表し;
R4は、水素又はメチルを表し;
そこで、R3がシアノを表す場合、R4は、水素以外の基を表す。
Xは窒素でありかつYは炭素であり、又はXは炭素でありかつYは窒素であり;
R1は、C1-4アルキル、C1-4アルコキシ、シアノ、又はモルフォリニルを表し;
m及びnは独立して、0〜1の整数を表し;
R2は、C1-4アルキルを表し;
R3は、ハロゲン、シアノ、トリフルオロメチル、トリフルオロメトキシ、又はジフルオロメトキシを表し;
R4は、水素又はメチルを表し;
そこで、R3がシアノを表す場合、R4は、水素以外の基を表し;
但し、該化合物は、以下の化合物でないことを条件とする:
1-[(4-クロロフェニル)スルホニル]-4-(2-ピリジニルカルボニル)ピペラジン;
1-[(4-クロロフェニル)スルホニル]-4-(4-ピリジニルカルボニル)ピペラジン;
1-(4-ピリジニルカルボニル)-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-(2-ピリジニルカルボニル)-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-(2-ピリジニルカルボニル)-4-({4-[(トリフルオロメチル)オキシ]フェニル}スルホニル)ピペラジン;及び
1-(4-ピリジニルカルボニル)-4-({4-[(トリフルオロメチル)オキシ]フェニル}スルホニル)ピペラジン。
第三又は第四の態様に関する一実施態様において、R3は、塩素、シアノ、トリフルオロメチル、トリフルオロメトキシ、又はジフルオロメトキシを表す。第三又は第四の態様に関するさらなる実施態様において、R3はトリフルオロメチルを表す。
第一〜第四の態様において定義したある化合物、又はその塩が、2つ以上の多形性形態で存在してもよいことは認められるであろう。本発明は、純粋な多形性形態であろうと、別の多形性形態などその他の材料と混合する場合であろうと、すべてのこのような形態に拡大する。
第一〜第四の態様において定義した化合物は、下記のスキームにおいて、及び実施例において示すとおり製造され得る。下記の方法は、本発明の別の態様を形成する。
(a)式(II)の化合物、又はその誘導体
(式中、R1、R2、R3、R4、R5、R6、X、Y、m、及びnは、先に定義したとおりであり、かつL1は、ハロゲン原子(例えば、塩素若しくは臭素)などの適切な脱離基、又は市販のアミドカップリング試薬(例えば、HOBT、HBTU、若しくはHATU)によって活性化されるヒドロキシル基を表す。);
(b)式(IV)の化合物
(式中、R1、R2、R3、R4、R5、R6、X、Y、m、及びnは、先に定義したとおりであり、かつL2は、ハロゲン原子(例えば、塩素又は臭素)などの適切な脱離基を表す。);
(c)第一〜第四の態様において定義した他の化合物との相互変換。
工程(i)は典型的に、温度範囲100〜180℃でのマイクロ波におけるイソプロパノールなどの適切な溶媒において、式(If)の化合物をアミンHNR1aR1bと、例えば1時間〜48時間など、(Ig)への良好な変換を達成するのに必要な時間、反応させることを含む。
工程(i)は典型的に、0℃〜大気温(例えば、大気温)において、適切な塩基(例えば、トリエチルアミン、ジ-イソプロピルエチルアミン、又はDIPEA)の存在下で、適切な溶媒(MeCN、THF、DMF、又はDCMなど)において、式(VI)の化合物を式(III)の化合物と反応させることを含む。
工程(ii)は典型的に、先の工程(ii)と類似の様式で実施してもよい脱保護反応を含む。
式(III)、(V)、及び(VI)の化合物は、市販されているか又は公知の方法によって製造されてもよいかのいずれかである。
「腸機能障害と関連した疼痛」には、非潰瘍性消化障害、非心臓性胸痛、及び過敏性腸症候群を含む。
第一〜第四の態様において定義した化合物によって潜在的に治療し得る別の容態は、痙縮又は筋高張性である。
このように、本発明は、さらなる態様において、第一〜第四の態様において定義した化合物又はその医薬として許容し得る塩を、さらなる1つの又は複数の治療薬と共に含む組み合わせを提供する。
Ar:アルゴン
aq.:水性
dba.:ジベンジリデンアセトン
DCM:ジクロロメタン
DIPEA:N,N-ジイソプロピルエチルアミン
DMF:N,N-ジメチルホルムアミド
DMSO:ジメチルスルホキシド
DPPF:1,1'-ビス(ジフェニルホスフィノ)フェロセン
EDC:塩酸1-エチル-3-(3-ジメチルアミノプロピル(dimethyllaminopropyl))カルボジイミド
EtOAc;酢酸エチル
HATU:ヘキサフルオロリン酸O-(7-アザベンゾトリアゾール-1-イル)-N,N,N',N'-テトラメチルウロニウム
HBTU:O-ベンゾトリアゾール-N,N,N',N'-テトラメチル-ウロニウム-ヘキサフルオロ-ホスファート
HOBT:ヒドロキシベンゾトリアゾール
iHex:イソヘキサン
LCMS:液体クロマトグラフィー質量分析
MS:質量分析
MeCN:アセトニトリル
MDAP:質量配向性自動調製用液体クロマトグラフィー
MeOH:メタノール
rt:室温
sat.:飽和した
SCX:強陽イオン交換クロマトグラフィー
SPE:固相抽出
SP4:Biotage-SP4(登録商標)自動精製システム
THF:テトラヒドロフラン
TFA:トリフルオロ酢酸
Pd2(dba)3:トリス(ジベンジリデンアセトン)ジパラジウム(0)
Pd(PPh3)4:テトラキス(トリフェニルホスフィン)パラジウム
h:時間
min:分
Boc:t-ブトキシカルボニル
PdCl2(dppf)3:(1,1'-ビス(ジフェニルホスフィノ)フェロセン)ジクロロパラジウム(II)
API-ES:大気圧イオン化エレクトロスプレー
下記の手順において、各出発材料の後に中間体に対する引用が典型的に提供される。これは、単に当業者に対する援助のために提供される。該出発材料は必ずしも、引用されるバッチから製造されなくてもよい。
(1-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
m/z (API-ES) 295 [M+H-100]+
4-{[4-(トリフルオロメチル)フェニル]スルホニル}-1-ピペラジンカルボン酸1,1-ジメチルエチル含有1,4-ジオキサン(100mL)の溶液に、4M HCl含有1,4-ジオキサン(50mL、200mmol)及び3滴の蒸留水を添加した。反応混合物を一晩撹拌した。次に、反応混合物を真空下で乾燥するまで減少させた。残渣をDCM(200mL)に溶解し、2M NaOH(50mL)で2回洗浄した。乾燥した硫酸マグネシウム上で有機層を乾燥させ、不溶性物質を濾過によって除去し、濾液を真空下で乾燥するまで減少させて、表題化合物(6.60g)を淡黄色の固体として生じた。
((3S)-3-メチル-1-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
(2S)-2-メチルピペラジン(15g、150mmol)をテトラヒドロフラン(300mL)に溶解し、溶液を0℃に冷却した。水酸化ナトリウム(150mL、449mmol)を添加した後、塩化4-(トリフルオロメチル)ベンゼンスルホニル(40g、164mmol)(200mLのTHFに溶解)を滴下して添加し、結果として生じる混合物を1時間撹拌した。塩化4-(トリフルオロメチル)ベンゼンスルホニル(0.06当量、2.2g)をさらに添加し、混合物を10分間撹拌した。混合物をDCM(500mL)及び水(500mL)で希釈し、5分間撹拌した。相を分離し、水性層をDCM(1000mL)で抽出し、有機相を減圧下で濃縮した。残渣を1M HCl(500mL)に取り、抽出した不純物のためにDCMで洗浄した。水性相を3M NaOHでpH=9に塩基性化し、DCM(3×500mL)で抽出し、組み合わせた有機相をNa2SO4上で乾燥させた後、溶媒を減圧下で除去して、表題化合物(30g)を与えた。
((3S)-4-[(4-クロロフェニル)スルホニル]-3-メチル-1-ピペラジンカルボン酸1,1-ジメチルエチル)
(塩酸(2S)-1-[(4-クロロフェニル)スルホニル]-2-メチルピペラジン)
(2,3'-ビピリジン-6'-カルボン酸)
((3R)-3-メチル-4-{[4-(トリフルオロメチル)フェニル]スルホニル}-1-ピペラジンカルボン酸1,1-ジメチルエチル)
(塩酸(2R)-2-メチル-1-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
((3S)-3-メチル-4-{[4-(トリフルオロメチル)フェニル]スルホニル}-1-ピペラジンカルボン酸1,1-ジメチルエチル)
(塩酸(2S)-2-メチル-1-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
((2S)-4-[(4-ブロモ-2-メチルフェニル)スルホニル]-2-メチル-1-ピペラジンカルボン酸1,1-ジメチルエチル)
((2S)-4-[(4-シアノ-2-メチルフェニル)スルホニル]-2-メチル-1-ピペラジンカルボン酸1,1-ジメチルエチル)
(3-メチル-4-{[(3S)-3-メチル-1-ピペラジニル]スルホニル}ベンゾニトリル)
((3R)-3-メチル-1-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン
((3R)-1-[(4-クロロフェニル)スルホニル]-3-メチルピペラジン)
m/z (API-ES) 274 + 276 (3:1) [M+H]+
(二塩酸(2S)-2-メチル-1-(2-ピリジニルカルボニル)ピペラジン)
m/z (API-ES) 206 [M+H]+
((2S)-2-メチル-1-[(2-メチル-4-ピリジニル)カルボニル]ピペラジン)
m/z (API-ES) 220 [M+H]+
(1-[(4-ブロモ-2-ピリジニル)カルボニル]-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
(塩酸(2S)-2-メチル-1-[(3-メチル-2-ピリジニル)カルボニル]-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
(1-[(6-メチル-2-ピリジニル)カルボニル]-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
(1-[(3-メチル-2-ピリジニル)カルボニル]-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
((2S)-2-メチル-1-(2-ピリジニルカルボニル)-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジンギ酸塩(1:1))
(2'-[(4-{[4-(トリフルオロメチル)フェニル]スルホニル}-1-ピペラジニル)カルボニル]-2,4'-ビピリジン)
(塩酸(2S)-1-[(4-クロロフェニル)スルホニル]-2-メチル-4-(2-ピリジニルカルボニル)ピペラジン)
(6'-[(4-{[4-(トリフルオロメチル)フェニル]スルホニル}-1-ピペラジニル)カルボニル]-2,3'-ビピリジン)
(1-(4-ピリジニルカルボニル)-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
(1-[(2-メチル-4-ピリジニル)カルボニル]-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
((2S)-2-メチル-1-[(2-メチル-4-ピリジニル)カルボニル]-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジンギ酸塩(1:1))
((2R)-4-[(4-クロロフェニル)スルホニル]-2-メチル-1-(2-ピリジニルカルボニル)ピペラジン)
m/z (API-ES) 380 +382 (3:1) [M+H]+
(4-{[(3S)-3-メチル-4-(2-ピリジニルカルボニル)-1-ピペラジニル]スルホニル}ベンゾニトリル)
m/z (API-ES) 371 [M+H]+
(4-({(3S)-3-メチル-4-[(2-メチル-4-ピリジニル)カルボニル]-1-ピペラジニル}スルホニル)ベンゾニトリル)
m/z (API-ES) 385 [M+H]+
(1-[(4-ブロモ-2-ピリジニル)カルボニル]-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
((2S)-1-[(4-クロロ-2-ピリジニル)カルボニル]-2-メチル-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
(塩酸N,N-ジメチル-2-[((2S)-2-メチル-4-{[4-(トリフルオロメチル)フェニル]スルホニル}-1-ピペラジニル)カルボニル]-4-ピリジンアミン)
m/z (API-ES) 457 [M+H]+
((2S)-1-{[4-(1-アゼチジニル)-2-ピリジニル]カルボニル}-2-メチル-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン)
(質量配向型自動HPLC/質量配向型自動調製(MDAP))
先の化合物において示される場合、下記の装置及び条件を使用して、質量配向型自動HPLCによる精製を実施した:
(ハードウェア)
Waters 2525二成分勾配モジュール
Waters 515構成ポンプ
Watersポンプ調節モジュール
Waters 2767注入回収機
Watersカラム流体工学管理装置
Waters 2996光ダイオードアレイ検出器
Waters ZQ質量分析計
Gilson 202画分回収機
Gilson Aspec廃棄物回収機
Waters MassLynx バージョン4 SP2
(カラム)
使用したカラムは、Waters Atlantisであり、その寸法は、19mm×100mm(小規模)及び30mm×100mm(大規模)である。固定相の粒子サイズは5μmである。
A:水性溶媒=水+0.1%ギ酸
B:有機溶媒=アセトニトリル+0.1%ギ酸
構成溶媒=メタノール:水(80:20)
針すすぎ溶媒=メタノール
関心対象の化合物の分析保持時間に応じて5つの方法を使用する。該方法の試行時間は13.5分であり、10分の勾配後の3.5分のカラムの洗い流し及び再平衡化工程を含んでいる。
大規模/小規模1.0〜1.5=5〜30%B
大規模/小規模1.5〜2.2=15〜55%B
大規模/小規模2.2〜2.9=30〜85%B
大規模/小規模2.9〜3.6=50〜99%B
大規模/小規模3.6〜5.0=80〜99%B(6分、続いて、7.5分の洗い流し及び再平衡化)
(流速)
先の方法はすべて、20mL/分(小規模)又は40mL/分(大規模)のいずれかの流速を有する。
液体クロマトグラフィー/質量分析(LC/MS)による先の化合物の分析を、下記の装置及び条件を使用して実施した:
(ハードウェア)
Waters Acquity二成分溶媒管理装置
Waters Acquityサンプル管理装置
Waters Acquity PDA
Waters ZQ質量分析計
Sedere Sedex 75
(ソフトウェア)
Waters MassLynx バージョン4.1
使用したカラムは、Waters Acquity BEH UPLC C18であり、その寸法は、2.1mm×50mmである。固定相の粒子サイズは、1.7μmである。
(溶媒)
A:水性溶媒=水+0.05%ギ酸
B:有機溶媒=アセトニトリル+0.05%ギ酸
弱い洗浄=1:1のメタノール:水
強い洗浄=水
使用した一般的な方法は、2分間の試行時間を有する。
一般的な方法についての注入容積は、0.5μLである。
カラム温度は、40℃である。
紫外線検出範囲は、220〜330nmである。
Biotage-SP4(登録商標)は、自動精製システムである。該システムは、あらかじめ負荷したシリカゲルカラムを使用する。使用者は、該材料をカラムの上部に適用して、溶媒、勾配、流速、カラムサイズ、回収方法、及び溶出容積を選択する。
(位相分離器(疎水性フリット))
位相分離器は、重力下で塩素化した溶媒から水性相を容易に分離する最適化したフリット材料に適合したある範囲のISOLUTE(登録商標)カラムである。
化合物において示される場合、SCXカートリッジを化合物精製方法の一部として使用した。典型的には、ISOLUTE SCX-2カートリッジを使用した。ISOLUTE SCX-2は、化学的に結合したプロピルスルホン酸官能基を有するシリカベースの収着媒である。
ISOLUTE SCX-2化学データ
基材:シリカ、50μm
官能基:プロピルスルホン酸
容量:0.6ミリ当量/g
対イオン:プロトン
本発明の化合物は、下記の研究に従って、hCav2.2アッセイにおけるインビトロでの生物活性について試験してもよい:
方法
細胞生物学
ヒトCav2.2α(α1B)サブユニットを、ヒトβ3及びα2δ1補助サブユニットと共に発現する安定発現株を、ヒト胎児由来腎臓(HEK293)細胞の連続的なトランスフェクション及び選択後に作製した。L-グルタミン(2mM;Invitrogen,カタログ番号25030-024)及び非必須アミノ酸(5%;Invitrogen,カタログ番号11140-035)を添加し10%ウシ胎仔血清を含むダルベッコ変法イーグル培地/F12培地(Invitrogen,カタログ番号041-95750V)において、HEK293細胞を培養した。まず、hCav2.2αサブユニット(ネオマイシン耐性マーカーを保有するpCIN5-hCav2.2)及びhCavβ3サブユニット(ハイグロマイシン耐性マーカーを保有するpCIH-hCavβ3)の発現のための2つのプラスミドベクターを使用して、HEK293細胞をトランスフェクトした。0.4mg mL-1ジェネティシンG418(Invitrogen,カタログ番号10131-027)及び0.1mg mL-1ハイグロマイシン(Invitrogen,カタログ番号10687-010)を補充した培地における選択後に、クローン細胞株を単離した。該クローン細胞株を、IonWorks平面アレイ電気生理学技術(以下に記載)を使用して、Cav2.2α/β3仲介性電流発現について評価した。適切なレベルの機能的Cav2.2α/β3電流発現を与えるクローン株を同定した。該細胞株に、ヒトα2δ1サブユニット(ピューロマイシン耐性マーカーを保有するpCIP-α2δ1)の発現のためのプラスミドベクターをトランスフェクトし、0.4mg mL-1ジェネティシンG418及び0.1mg mL-1ハイグロマイシンに加えて、0.62μg mL-1ピューロマイシン(Sigma,カタログ番号P-7255)を含む培地における選択後にクローン細胞株を単離した。強いレベルのCav2.2α/β3/α2δ1仲介性電流発現を与えるいくつかの細胞株を同定し、これらのうちの1つを化合物の特徴づけのために選択した。この細胞株内の3つのサブユニットすべての発現を、G418(0.4mg mL-1)、ハイグロマイシン(0.1mg mL-1)、及びピューロマイシン(0.62μg mL-1)の封入によって持続的に維持した。大気中に5%CO2を含む高湿環境において37℃で細胞を維持した。細胞を経代のためにT175培養フラスコからはがし、TrpLE(Invitrogen,カタログ番号12604-013)を使用して回収した。
細胞をT175フラスコにおいて30〜60%コンフルエンスに増殖させ、30℃で24時間維持した後に記録した。増殖培地を除去し、Ca2+を含まないPBS(Invitrogen,カタログ番号14190-094)で洗浄し、3mLの加温した(37℃)TrpLE(Invitrogen,カタログ番号12604-013)と共に6分間インキュベートすることによって、細胞を浮揚させた。浮揚した細胞を10mLの細胞外緩衝液に懸濁した。次に、細胞懸濁液を15mLチューブに入れ、700rpmで2分間遠心分離した。遠心分離後、上清を除去し、細胞ペレットを4.5mLの細胞外溶液に再懸濁した。
IonWorks平面アレイ電気生理学技術(Molecular Devices Corp.)を使用して、電流を室温(21〜23℃)で記録した。刺激プロトコール及びデータ獲得を、マイクロコンピュータ(Dell Pentium 4)を使用して実施した。平面電極孔抵抗(Rp)を決定するために、10mV、160ミリ秒の電位差を各孔に適用した。該測定を実施した後に細胞を付加した。細胞付加後、密封試験を実施した後、抗生物質(アンホテリシン)を循環させて、細胞内アクセスを達成した。試験パルスの200ミリ秒前に160ミリ秒の過分極(10mV)前パルスを適用して、漏れコンダクタンスを測定することによって、すべての実験において漏れの減算を行った。−90mV〜+10mVの保持電位(VH)から段階的に行う試験パルスを20ミリ秒間適用し、10Hzの頻度で10回反復した。すべての実験において、試験パルスプロトコールを化合物の不在下(読み取り前)及び存在下(読み取り後)で実施した。読み取り前及び読み取り後を、化合物の添加後に3〜3.5分間インキュベートすることによって分離した。
細胞内溶液は、(mMにおいて)下記を含んでいた:グルコン酸K 120、KCl 20mM、MgCl2 5、EGTA 5、HEPES 10、pH7.3に調整。アンホテリシンを30mg/mLストック溶液として調製し、細胞内緩衝溶液における0.2mg mL-1の最終作業濃度に希釈した。細胞外溶液は、(mMにおいて)下記を含んでいた:グルコン酸Na 120、NaCl 120、MgCl2 1、HEPES 10、BaCl2 5、pH7.4に調整。
化合物をDMSOにおいて10mMストック溶液として調製し、その後1:3の連続希釈を実施した。最終的に、化合物を外部溶液において1:100に希釈し、結果として1%のDMSO終濃度を生じた。
化合物の不在下における密封抵抗(40MΩ超)、抵抗低下(35%超)、及びピーク電流振幅(200pA超)を使用して、記録を分析及びフィルター処理し、適していない細胞をさらなる分析から除外した。化合物の添加前と化合物の添加後の対比較を使用して、各化合物の阻害効果を決定した。第一の脱分極パルスによって惹起される電流を50%阻害するのに必要な化合物の濃度(持続性pIC50)を、濃度反応データへのHill式の適合によって決定した。加えて、第10回目対第1回目の脱分極パルスに及ぼす化合物の効果を評価することによって、化合物の使用依存性阻害特性を決定した。第10回目と第1回目のパルスの比を、薬剤の不在下及び存在下で決定し、%使用依存阻害を算出した。持続性pIC50についてのものと同一の式を使用してデータを適合させ、30%阻害を生じる濃度(使用依存性pUD30)を決定した。
化合物1〜15、及び17〜19は、5.0以下の平均pIC50値を呈した。化合物1〜15は、4.5以下の平均pIC50値を呈した。
Claims (28)
- 治療において使用するための式Iの化合物、又はその医薬として許容し得る塩:
m及びnは独立して、0、1、及び2から選択され;
ここで、存在する場合、各R1は独立して、C1-4アルキル、C1-4アルコキシ、C3-6シクロアルキル、シアノ、NR1aR1b、及びハロゲンから選択され;
R1a及びR1bは独立して、水素、C1-4アルキル、C3-6シクロアルキル、及び4〜6員のヘテロシクリルから選択され;又はR1a及びR1bは、それらが結合する窒素原子と共に、4〜6員の複素環を形成し;
ここで、存在する場合、各R2は、C1-4アルキルであり;
R3は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4ハロアルコキシであり;
R4は、水素又はC1-4アルキルであり;
R5は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4ハロアルコキシであり;
R6は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4ハロアルコキシであり;
そこで、R3、R4、R5、及びR6のうちの少なくとも1つは、水素以外の基である。)。 - R1が、C1-4アルキル、C1-4アルコキシ、シアノ、及びNR1aR1bから選択される、請求項1記載の化合物、又はその医薬として許容し得る塩。
- R1が、C1-4アルキル及びC1-4アルコキシから選択される、請求項2記載の化合物、又はその医薬として許容し得る塩。
- R1が、メチル及びメトキシから選択される、請求項3記載の化合物、又はその医薬として許容し得る塩。
- R1が、2-メチル、6-メチル、2-メトキシ、及び6-メトキシから選択される、請求項4記載の化合物、又はその医薬として許容し得る塩。
- R1が2-メチルである、請求項5記載の化合物、又はその医薬として許容し得る塩。
- R1が、NR1aR1bであり、かつR1a及びR1bが独立して、水素及びC1-4アルキルから選択され、又はR1a及びR1bが、それらの結合する窒素原子と共に4〜6員の複素環を形成する、請求項1記載の化合物、又はその医薬として許容し得る塩。
- R1a及びR1bがC1-4アルキルであり、又はR1a及びR1bがそれらの結合する窒素原子と共に4員又は5員の複素環を形成する、請求項7記載の化合物、又はその医薬として許容し得る塩。
- R1a及びR1bがC1-4アルキルであり、又はR1a及びR1bが、それらの結合する窒素原子と共に、モルフォリニル環、ピロリジニル環、又はアゼチジニル環を形成する、請求項8記載の化合物、又はその医薬として許容し得る塩。
- R1a及びR1bがC1-4アルキルである、請求項9記載の化合物、又はその医薬として許容し得る塩。
- R1a及びR1bが、メチル及びエチルから選択される、請求項10記載の化合物、又はその医薬として許容し得る塩。
- nが0又は1である、請求項1〜11のいずれか一項記載の化合物、又はその医薬として許容し得る塩。
- nが1である、請求項12記載の化合物、又はその医薬として許容し得る塩。
- R2がメチルである、請求項1〜13のいずれか一項記載の化合物、又はその医薬として許容し得る塩。
- R2がメチルであり、かつmが1である、請求項14記載の化合物、又はその医薬として許容し得る塩。
- R3が、C1-4ハロアルキル又はC1-4ハロアルコキシである、請求項1〜17のいずれか一項記載の化合物、又はその医薬として許容し得る塩。
- R3が、トリフルオロメチル、トリフルオロメトキシ、又はジフルオロメトキシである、請求項18記載の化合物、又はその医薬として許容し得る塩。
- R4が、水素又はメチルである、請求項1〜19のいずれか一項記載の化合物、又はその医薬として許容し得る塩。
- R4が水素である、請求項20記載の化合物、又はその医薬として許容し得る塩。
- R5及びR6が独立して、水素及びC1-4ハロアルキルから選択される、請求項1〜21のいずれか一項記載の化合物、又はその医薬として許容し得る塩。
- R5及びR6が独立して、水素及びトリフルオロメチルから選択され、特にR5及びR6が水素である、請求項22記載の化合物、又はその医薬として許容し得る塩。
- 疼痛の治療において使用するための、請求項1〜23のいずれか一項記載の化合物、又はその医薬として許容し得る塩。
- 疼痛の治療のための薬剤の製造における、請求項1〜23のいずれか一項記載の化合物又はその医薬として許容し得る塩の使用。
- 疼痛の治療を必要とするヒトに、治療的有効量の請求項1〜23のいずれか一項記載の化合物又はその医薬として許容し得る塩を投与することを含む、該ヒトにおける疼痛の治療のための方法。
- (a)請求項1〜23のいずれか一項記載の化合物、又はその医薬として許容し得る塩と、(b)医薬として許容し得る賦形剤とを含む医薬組成物。
- 式(I)の化合物
(式中、Xは窒素であり、かつYは炭素であり、又はXは炭素であり、かつYは窒素であり;
m及びnは独立して、0、1、及び2から選択され;
ここで、存在する場合、各R1は独立して、C1-4アルキル、C1-4アルコキシ、C3-6シクロアルキル、シアノ、NR1aR1b、及びハロゲンから選択され;
R1a及びR1bは独立して、水素、C1-4アルキル、C3-6シクロアルキル、及び4〜6員のヘテロシクリルから選択され;又はR1a及びR1bは、それらが結合する窒素原子と共に、4〜6員の複素環を形成し;
ここで、存在する場合、各R2はC1-4アルキルであり;
R3は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4ハロアルコキシであり;
R4は、水素又はC1-4アルキルであり;
R5は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4ハロアルコキシであり;
R6は、水素、ハロゲン、シアノ、C1-4ハロアルキル、又はC1-4 ハロアルコキシであり;
そこで、R3、R4、R5、及びR6のうちの少なくとも1つは、水素以外の基であり、但し、該化合物は、以下の化合物でないことを条件とする:
1- [(4-クロロフェニル)スルホニル]-4-(2-ピリジニルカルボニル)ピペラジン;
1-[(4-クロロフェニル)スルホニル]-4-[(4-クロロ-2-ピリジニル)カルボニル]ピペラジン;
1-[(3-クロロフェニル)スルホニル]-4-(4-ピリジニルカルボニル)ピペラジン;
1-[(4-クロロフェニル)スルホニル]-4-(4-ピリジニルカルボニル)ピペラジン;
1-{[4-クロロ-3-(トリフルオロメチル)フェニル]スルホニル}-4-(2-ピリジニルカルボニル)ピペラジン;
1-[(4-クロロ-2-ピリジニル)カルボニル]-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-{[4-クロロ-3-(トリフルオロメチル)フェニル]スルホニル}-4-(4-ピリジニルカルボニル)ピペラジン;
1-(4-ピリジニルカルボニル)-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-(4-ピリジニルカルボニル)-4-{[3-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-(2-ピリジニルカルボニル)-4-{[3-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-(2-ピリジニルカルボニル)-4-{[4-(トリフルオロメチル)フェニル]スルホニル}ピペラジン;
1-(2-ピリジニルカルボニル)-4-({4-[(トリフルオロメチル)オキシ]フェニル}スルホニル)ピペラジン;
1-(4-ピリジニルカルボニル)-4-({4-[(トリフルオロメチル)オキシ]フェニル}スルホニル)ピペラジン;及び
1-{[3,5-ビス(トリフルオロメチル)フェニル]スルホニル}-4-(4-ピリジニルカルボニル)ピペラジン)。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0813142.7 | 2008-07-17 | ||
GBGB0813142.7A GB0813142D0 (en) | 2008-07-17 | 2008-07-17 | Novel compounds |
PCT/EP2009/059011 WO2010007072A1 (en) | 2008-07-17 | 2009-07-15 | Piperazine derivatives used as cav2.2 calcium channel modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011528019A true JP2011528019A (ja) | 2011-11-10 |
JP5688850B2 JP5688850B2 (ja) | 2015-03-25 |
Family
ID=39737239
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011517911A Expired - Fee Related JP5543966B2 (ja) | 2008-07-17 | 2009-07-15 | Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体 |
JP2011517910A Expired - Fee Related JP5688850B2 (ja) | 2008-07-17 | 2009-07-15 | Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011517911A Expired - Fee Related JP5543966B2 (ja) | 2008-07-17 | 2009-07-15 | Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体 |
Country Status (19)
Country | Link |
---|---|
US (3) | US8530478B2 (ja) |
EP (2) | EP2346828B1 (ja) |
JP (2) | JP5543966B2 (ja) |
KR (1) | KR101599087B1 (ja) |
CN (1) | CN102099337B (ja) |
AR (1) | AR072809A1 (ja) |
AU (1) | AU2009272762B2 (ja) |
BR (1) | BRPI0916622A2 (ja) |
CA (1) | CA2730471C (ja) |
EA (1) | EA018621B1 (ja) |
ES (2) | ES2396962T3 (ja) |
GB (1) | GB0813142D0 (ja) |
IL (1) | IL210446A (ja) |
MX (1) | MX2011000600A (ja) |
PL (1) | PL2300432T3 (ja) |
TW (1) | TW201016677A (ja) |
UY (1) | UY31990A (ja) |
WO (2) | WO2010007073A1 (ja) |
ZA (1) | ZA201100014B (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0813142D0 (en) * | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
GB201000685D0 (en) * | 2010-01-15 | 2010-03-03 | Glaxo Group Ltd | Novel compounds |
JP6058556B2 (ja) * | 2011-01-19 | 2017-01-11 | クオンベルゲンセ プハルマセウトイカルス リミテッド | CaV2.2カルシウムチャンネルブロッカーとしてのピペラジン誘導体 |
WO2013000651A1 (en) | 2011-06-27 | 2013-01-03 | Newron Pharmaceuticals S.P.A. | Fluorinated arylalkylaminocarboxamide derivatives |
CA2945529A1 (en) * | 2014-04-14 | 2015-10-22 | Grunenthal Gmbh | Aryl substituted heterocyclyl sulfones |
MX2016013447A (es) * | 2014-04-14 | 2017-01-18 | Gruenenthal Gmbh | Heterociclilsulfonas heteroarilo sustituidas. |
GB201516183D0 (en) * | 2015-09-14 | 2015-10-28 | Calchan Ltd | Novel pharmaceutical composition |
TW201718557A (zh) | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
TW201726128A (zh) | 2015-10-08 | 2017-08-01 | 歌林達有限公司 | 經吡唑基取代之四氫哌喃基碸 |
KR102654466B1 (ko) * | 2017-04-26 | 2024-04-08 | 카비온, 인코포레이티드 | 기억 및 인지 개선 방법 및 기억 및 인지 장애 치료 방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007111921A1 (en) * | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
WO2008024284A2 (en) * | 2006-08-21 | 2008-02-28 | Merck & Co., Inc. | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988006371A1 (en) | 1987-02-13 | 1988-08-25 | Mitsubishi Denki Kabushiki Kaisha | Starter/charger of engine |
US5112824A (en) * | 1989-12-08 | 1992-05-12 | Merck & Co., Inc. | Benzofuran compounds as class III antiarrhythmic agents |
US5498711A (en) | 1993-02-03 | 1996-03-12 | Thiokol Corporation | Synthesis of 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo[5.5.0.05,903,11]dodecane |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
ES2183935T3 (es) | 1995-02-13 | 2003-04-01 | Searle & Co | Isoxazoles sustituidos para el tratamiento de la inflamacion. |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
WO1996031501A1 (en) | 1995-04-07 | 1996-10-10 | Schering Corporation | Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase |
UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
FR2744450A1 (fr) | 1996-02-02 | 1997-08-08 | Pf Medicament | Nouvelles naphtylpiperazines derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
CN1098256C (zh) | 1996-04-12 | 2003-01-08 | G·D·瑟尔公司 | 作为cox-2抑制剂前药的取代的苯磺酰胺衍生物 |
US5880128A (en) * | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
EE03680B1 (et) | 1996-07-18 | 2002-04-15 | Merck Frosst Canada & Co. / Merck Frosst Canada &Cie. | Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid |
AU4722197A (en) | 1996-10-22 | 1998-05-15 | Daiichi Pharmaceutical Co., Ltd. | Novel remedies for infectious diseases |
GB9623283D0 (en) | 1996-11-08 | 1997-01-08 | Zeneca Ltd | Heterocyclic derivatives |
UA56197C2 (uk) | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
AU7453498A (en) | 1997-05-30 | 1998-12-30 | Takeda Chemical Industries Ltd. | Sulfonamide derivatives, their production and use |
GB9715894D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic derivatives |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
YU11900A (sh) | 1997-09-05 | 2002-11-15 | Glaxo Group Limited | Derivati 2,3-diaril-pirazolo (1,5-b) piridazina, njihovo dobijanje i njihova upotreba kao inhibitora ciklooksigenaze 2(cox-2) |
AU745425B2 (en) | 1998-01-27 | 2002-03-21 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl factor Xa inhibitors |
WO2000012074A2 (en) | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
ES2228127T3 (es) | 1998-11-03 | 2005-04-01 | Glaxo Group Limited | Derivados de pirazolopiridina como inhibidores selectivos de cox-2. |
WO2000038683A1 (en) * | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | THROMBIN OR FACTOR Xa INHIBITORS |
AUPP818099A0 (en) | 1999-01-14 | 1999-02-11 | Fujisawa Pharmaceutical Co., Ltd. | New n-containing heterocyclic compounds |
US6498166B1 (en) | 1999-02-27 | 2002-12-24 | Smithkline Beecham Corporation | Pyrazolopyridines |
GB9927844D0 (en) | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
WO2001064676A2 (en) | 2000-02-28 | 2001-09-07 | Scios, Inc. | INHIBITORS OF p38-α KINASE |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
WO2001076693A1 (en) | 2000-04-10 | 2001-10-18 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
FR2812198B1 (fr) | 2000-07-28 | 2008-07-18 | Sod Conseils Rech Applic | DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25 |
GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
EP1389204A4 (en) | 2001-04-26 | 2005-03-23 | Kolon Inc | NEW SULPHONAMIDE DERIVATIVES, THEIR INTERMEDIATES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THESE COMPOUNDS |
DE10155684A1 (de) | 2001-11-13 | 2003-05-22 | Bayer Ag | Thiazolharnstoffe |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
FR2833261B1 (fr) | 2001-12-06 | 2004-07-02 | Yang Ji Chemical Company Ltd | Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii |
KR100464261B1 (ko) | 2002-01-24 | 2005-01-03 | 주식회사 파나진 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
NZ534830A (en) | 2002-03-13 | 2005-08-26 | Janssen Pharmaceutica Nv | Compounds with histone deacetylase HDAC inhibiting activity and oral bioavailability useful for treating proliferative diseases |
DE10217006A1 (de) | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
NZ535763A (en) | 2002-04-18 | 2007-06-29 | Schering Corp | (1-4-piperidinyl) benzimidazole derivatives useful as histamine H3 antagonists |
CN1181065C (zh) * | 2002-05-08 | 2004-12-22 | 上海医药工业研究院 | 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用 |
DE10319435B4 (de) * | 2003-04-25 | 2018-07-26 | Whitecryption Corporation | Verfahren zur Verarbeitung von Daten zum Schutz eines Softwareprogramms vor Rekonstruktion |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
US20050277629A1 (en) | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
EP1758884A2 (en) | 2004-05-20 | 2007-03-07 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
DE102004035672A1 (de) | 2004-07-22 | 2006-03-30 | Windmöller & Hölscher Kg | Verkürzte Stapelbildung |
AU2005286731A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
DE102004054053A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102005013967A1 (de) | 2004-11-05 | 2006-10-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
JP5140577B2 (ja) | 2005-03-31 | 2013-02-06 | タケダ カリフォルニア インコーポレイテッド | ヒドロキシステロイドデヒドロゲナーゼ阻害剤 |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
EP1966132A2 (en) | 2005-12-15 | 2008-09-10 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
EP1966143A2 (en) * | 2005-12-21 | 2008-09-10 | Schering Corporation | Substituted aniline derivatives useful as histamine h3 antagonists |
JP2009521444A (ja) | 2005-12-22 | 2009-06-04 | メルク エンド カムパニー インコーポレーテッド | カルシウムチャンネルブロッカーとなる置換ピペリジン |
US7625880B2 (en) | 2006-01-13 | 2009-12-01 | Pharmacyclics, Inc. | Inhibitors of tyrosine kinases and uses thereof |
WO2007103456A2 (en) | 2006-03-06 | 2007-09-13 | Trimeris, Inc. | Piperazine and piperidine biaryl derivatives |
WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
WO2007118854A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
JP5539717B2 (ja) | 2006-07-14 | 2014-07-02 | 塩野義製薬株式会社 | オキシム化合物およびその使用 |
JPWO2008023720A1 (ja) | 2006-08-23 | 2010-01-14 | アステラス製薬株式会社 | ウレア化合物又はその塩 |
WO2008048914A1 (en) | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Polycyclic compounds which modulate the cb2 receptor |
WO2008075012A1 (en) | 2006-12-18 | 2008-06-26 | 7Tm Pharma A/S | Cb1 receptor modulators |
US7648979B2 (en) * | 2007-02-07 | 2010-01-19 | Hoffmann-La Roche Inc. | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives |
US7507736B2 (en) * | 2007-02-07 | 2009-03-24 | Hoffmann-La Roche Inc. | Indol-2-yl-piperazin-1-yl-methanone derivatives |
WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
ES2422603T3 (es) | 2007-05-31 | 2013-09-12 | Shionogi & Co | Compuestos oxiimino y el uso de estos |
JP5380435B2 (ja) | 2007-05-31 | 2014-01-08 | ユーロ−セルティーク ソシエテ アノニム | アミド化合物およびその使用 |
US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
AU2008307572A1 (en) | 2007-10-04 | 2009-04-09 | Merck Sharp & Dohme Corp. | Substituted aryl sulfone derivatives as calcium channel blockers |
GB0813142D0 (en) * | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
-
2008
- 2008-07-17 GB GBGB0813142.7A patent/GB0813142D0/en not_active Ceased
-
2009
- 2009-07-15 EP EP09780586A patent/EP2346828B1/en not_active Not-in-force
- 2009-07-15 CA CA2730471A patent/CA2730471C/en not_active Expired - Fee Related
- 2009-07-15 BR BRPI0916622-0A patent/BRPI0916622A2/pt not_active IP Right Cessation
- 2009-07-15 WO PCT/EP2009/059012 patent/WO2010007073A1/en active Application Filing
- 2009-07-15 US US13/054,265 patent/US8530478B2/en not_active Expired - Fee Related
- 2009-07-15 EA EA201170209A patent/EA018621B1/ru not_active IP Right Cessation
- 2009-07-15 EP EP09780587A patent/EP2300432B1/en not_active Not-in-force
- 2009-07-15 US US12/503,125 patent/US8288388B2/en not_active Expired - Fee Related
- 2009-07-15 AU AU2009272762A patent/AU2009272762B2/en not_active Ceased
- 2009-07-15 JP JP2011517911A patent/JP5543966B2/ja not_active Expired - Fee Related
- 2009-07-15 ES ES09780587T patent/ES2396962T3/es active Active
- 2009-07-15 CN CN200980127788XA patent/CN102099337B/zh not_active Expired - Fee Related
- 2009-07-15 AR ARP090102692A patent/AR072809A1/es unknown
- 2009-07-15 ES ES09780586T patent/ES2396960T3/es active Active
- 2009-07-15 UY UY0001031990A patent/UY31990A/es unknown
- 2009-07-15 KR KR1020117001109A patent/KR101599087B1/ko not_active IP Right Cessation
- 2009-07-15 JP JP2011517910A patent/JP5688850B2/ja not_active Expired - Fee Related
- 2009-07-15 PL PL09780587T patent/PL2300432T3/pl unknown
- 2009-07-15 MX MX2011000600A patent/MX2011000600A/es active IP Right Grant
- 2009-07-15 WO PCT/EP2009/059011 patent/WO2010007072A1/en active Application Filing
- 2009-07-15 TW TW098123842A patent/TW201016677A/zh unknown
-
2011
- 2011-01-03 IL IL210446A patent/IL210446A/en not_active IP Right Cessation
- 2011-01-03 ZA ZA2011/00014A patent/ZA201100014B/en unknown
-
2012
- 2012-08-07 US US13/568,211 patent/US8536183B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007111921A1 (en) * | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
WO2008024284A2 (en) * | 2006-08-21 | 2008-02-28 | Merck & Co., Inc. | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
Non-Patent Citations (15)
Title |
---|
JPN7013004422; Database REGISTRY on STN,879744-21-5/RN,Entered ST * |
JPN7013004423; Database REGISTRY on STN,333756-54-0/RN,Entered ST * |
JPN7013004425; Database REGISTRY on STN,1009951-42-1/RN,Entered S * |
JPN7013004426; Database REGISTRY on STN,1013261-59-0/RN,Entered S * |
JPN7013004427; Database REGISTRY on STN,850020-28-9/RN,Entered ST * |
JPN7013004428; Database REGISTRY on STN,879772-04-0/RN,Entered ST * |
JPN7013004429; Database REGISTRY on STN,1012528-09-4/RN,Entered S * |
JPN7013004430; Database REGISTRY on STN,791082-88-7/RN,Entered ST * |
JPN7013004431; Database REGISTRY on STN,1031199-34-4/RN,Entered S * |
JPN7013004432; Database REGISTRY on STN,879337-04-9/RN,Entered ST * |
JPN7013004433; Database REGISTRY on STN,850018-38-1/RN,Entered ST * |
JPN7013004434; Database REGISTRY on STN,1009896-34-7/RN,Entered S * |
JPN7013004435; Database REGISTRY on STN,461428-49-9/RN,Entered ST * |
JPN7013004436; Database REGISTRY on STN,849191-30-6/RN,Entered ST * |
JPN7013004437; Database REGISTRY on STN,633321-74-1/RN,Entered ST * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5688850B2 (ja) | Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体 | |
AU2017232906A1 (en) | Small molecules against cereblon to enhance effector T cell function | |
CN101939053A (zh) | 可溶性的鸟苷酸环化酶活化剂 | |
AU2005218555A1 (en) | Dimeric small molecule potentiators of apoptosis | |
BR112016017317B1 (pt) | Composto, e, uso de um composto | |
CN104039766A (zh) | 药物化合物 | |
JP5611201B2 (ja) | ピラゾロ[1,5−a]ピリミジン誘導体 | |
CN114126616A (zh) | Bcl-2抑制剂的纳米颗粒制剂 | |
CN110582495B (zh) | 作为tnf活性的调节剂的稠合五环咪唑衍生物 | |
BR112020008371A2 (pt) | novos derivados de alcoxiamino para tratamento de dor e condições relacionadas à dor | |
CN115466243A (zh) | 用于tead抑制剂的杂环化合物 | |
JP5785953B2 (ja) | CaV2.2カルシウムチャンネルを遮断するためのピペラジン誘導体 | |
JP2013526512A (ja) | 新規化合物 | |
JP6058556B2 (ja) | CaV2.2カルシウムチャンネルブロッカーとしてのピペラジン誘導体 | |
JP2022514344A (ja) | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120711 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131210 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140304 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140414 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140617 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141016 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150126 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5688850 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |